Annex 2. Methods
A2.3 Financing TB control (2002-2008)
A2.3.1 Data collection
We collected data from five main sources: NTPs, the WHO-CHOICE team,1 Global Fund proposals and databases, previous WHO reports in this series, and epidemiological and financial analyses carried out for the Global Plan.2 In 2007, data were collected directly from countries using a two-page questionnaire included in the standard WHO data collection form (described above in A2.1). NTP managers were asked to complete three tables. The first two tables required a summary of the NTP budget for fiscal years 2007 and 2008, in US$, by line item and source of funding (including a column for funding gaps). The third table requested NTP expenditure data for 2006, by line item and source of funding. The form also requested information about infrastructure dedicated to TB control and the ways in which general health infrastructure is used for TB control (e.g. the number of dedicated TB beds available, the number of outpatient visits that patients need to make to a health facility during treatment and the average length of stay when patients are admitted to hospital). We also asked for an estimate of the number of patients who would be treated in 2007 and 2008, for (a) smear-positive and (b) smear-negative and extrapulmonary cases combined.
Line items for the budget tables were designed to be in line with the Stop TB Strategy and to allow for comparisons with the cost categories used in the Global Plan. A total of 14 line items were defined: first-line drugs; dedicated NTP staff; routine programme management and supervision activities; laboratory supplies and equipment; PAL; PPM; second-line drugs for MDR-TB; management of MDR-TB (budget excluding second-line drugs); collaborative TB/HIV activities; ACSM; community-based care; operational research; surveys of disease prevalence and infection; and all other budget lines for TB (e.g. technical assistance). The relationship of these items to the Stop TB Strategy and the Global Plan and the categories used for presentation of financial analyses in this report are shown in Table A2.2.
1 The WHO-CHOICE (CHOosing Interventions that are Cost-Effective) team conducts work on the costs and effects of a wide range of health interventions.
2 The Global Plan to Stop TB, 2006-2015: methods used to assess costs, funding and funding gaps. Geneva, Stop TB Partnership and World Health Organization, 2006 (WHO/HTM/STB/2006.38).